Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients

We evaluated the safety and efficacy of intrapericardial bevacizumab (BEV) for treating symptomatic malignant pericardiac effusion (MPCE) in seven advanced cancer patients. All patients had previously undergone multiple lines of systemic therapy. Each patient received paracentesis and intrapericardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dawei, Zhang, Yan, Shi, Fang, Zhu, Hui, Li, Minghuan, Chen, Kaijun, Kong, Li, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239564/
https://www.ncbi.nlm.nih.gov/pubmed/27203219
http://dx.doi.org/10.18632/oncotarget.9420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239564/
https://www.ncbi.nlm.nih.gov/pubmed/27203219
http://dx.doi.org/10.18632/oncotarget.9420

Ejemplares similares